Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Saniona AB ( (SE:SANION) ) just unveiled an announcement.
Saniona AB announced that Fenja Capital II A/S has requested the conversion of its remaining outstanding convertibles, totaling SEK 6 million, into shares. This conversion will result in the issuance of 1,941,747 new shares, increasing the total number of shares by approximately 1.41% and slightly diluting existing shares and votes. The move reflects Saniona’s ongoing financial maneuvers to manage its capital structure effectively.
More about Saniona AB
Saniona is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. It has a diverse internal pipeline targeting conditions like epilepsy and major depressive disorder, and engages in strategic collaborations with companies such as Acadia Pharmaceuticals and Productos Medix. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market.
Average Trading Volume: 693,017
Current Market Cap: SEK1.36B
For detailed information about SANION stock, go to TipRanks’ Stock Analysis page.